HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 289/6/E1044    most recent 00209.2005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Ferone, D. Articles by Barreca, A. Search for Related Content PubMed PubMed Citation Articles by Ferone, D. Articles by Barreca, A.

Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation

Diego Ferone,¹ Marica Arvigo,¹ Claudia Semino,¹ Philippe Jaquet,² Alexandru Saveanu,² John E. Taylor,³ Jacques-Pierre Moreau,³ Michael D. Culler,³ Manuela Albertelli,¹ Francesco Minuto,¹ and Antonina Barreca^1,

¹Department of Endocrinological and Metabolic Sciences and Centre for Excellence for Biomedical Research, University of Genova, Genova, Italy; ²Interactions Cellulaires Neuroendocriniennes, Unité Mixte de Recherche 6544, Faculté de Médecine Nord, Centre National de la Recherche Scientifique, Institut Fédératif Jean Roche, Marseille Cedex, France; and ³Biomeasure Incorporated/Ipsen, Milford, Massachusetts

Submitted 10 May 2005 ; accepted in final form 21 July 2005

To study somatostatin/dopamine (SS/D) synergy in a human cell system constitutively expressing SS and D receptors (SSR and DR, respectively), we characterized the expression of SSR and DR subtypes in the non-small-cell lung cancer line Calu-6, and then we evaluated the effect on cell proliferation of SS/D chimeric molecules (BIM-23A387 and BIM-23A370), which bind with high affinity both sst₂ and D₂R, and compared the results with those obtained by using SS-14 and subtype-selective SS analogs (SSA) and D agonists (DA). Because Calu-6 cells produce insulin-like growth factor (IGF) and IGF-binding protein (IGFBP) peptides, which play a role in the autocrine/paracrine control of cell growth, we also investigated the effects of chimeric compounds on secretion and expression of IGF system components. Relative high levels of sst₂ and the long isoform of the D₂R were detected by real-time RT-PCR and Western blot in Calu-6, together with sst₅ and to a lesser extent sst₃ and D₄R. BIM-23A387 and BIM-23A370 significantly inhibited growth of Calu-6, whereas IGF-IGFBP secretion or expression was unaffected, suggesting a direct inhibitory effect. The inhibition of cell growth, measured by both [³H]thymidine incorporation and cell count, was significantly lower when individual SSA and DA control peptides or subtype-specific SSA and DA were tested. BIM-23A370 was more potent than BIM-23A387 (P < 0.001). These findings show that SS/D chimeras can inhibit Calu-6 proliferation in an IGF-independent manner and suggest that this enhanced potency might be because of the induction of SSR/DR dimerization. The Calu-6 cell line, constitutively expressing SSR and DR, provides a suitable model to elucidate the mechanism of action of SSA and DA on regulation of cell growth and to characterize the interaction between SSR and DR.

somatostatin receptors; dopamine receptors; receptor dimerization; growth factors; lung carcinoma

This article has been cited by other articles:

				T. Florio, F. Barbieri, R. Spaziante, G. Zona, L. J Hofland, P. M van Koetsveld, R. A Feelders, G. K Stalla, M. Theodoropoulou, M. D Culler, et al. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study Endocr. Relat. Cancer, June 1, 2008; 15(2): 583 - 596. [Abstract] [Full Text] [PDF]

				D. Ferone, A. Saveanu, M. D Culler, M. Arvigo, A. Rebora, F. Gatto, F. Minuto, and P. Jaquet Novel chimeric somatostatin analogs: facts and perspectives Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S23 - S28. [Abstract] [Full Text] [PDF]

				D. Ferone, R. Pivonello, E. Resmini, M. Boschetti, A. Rebora, M. Albertelli, V. Albanese, A. Colao, M. D Culler, and F. Minuto Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S37 - S43. [Abstract] [Full Text] [PDF]

				D. O'Toole, A. Saveanu, A. Couvelard, G. Gunz, A. Enjalbert, P. Jaquet, P. Ruszniewski, and A. Barlier The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies Eur. J. Endocrinol., December 1, 2006; 155(6): 849 - 857. [Abstract] [Full Text] [PDF]

				D. FERONE, M. BOSCHETTI, E. RESMINI, M. GIUSTI, V. ALBANESE, U. GOGLIA, M. ALBERTELLI, L. VERA, F. BIANCHI, and F. MINUTO Neuroendocrine-Immune Interactions: The Role of Cortistatin/Somatostatin System Ann. N.Y. Acad. Sci., June 1, 2006; 1069(1): 129 - 144. [Abstract] [Full Text] [PDF]

				L. Bodei, G. Paganelli, and G. Mariani Receptor Radionuclide Therapy of Tumors: A Road from Basic Research to Clinical Applications J. Nucl. Med., March 1, 2006; 47(3): 375 - 377. [Full Text] [PDF]